Studies in SCD and MCI focus on conversion risk at prodromal stages, whereas our analysis targets patients with established AD, highlighting the heterogeneity of progression and the ability of plasma NfL to distinguish fast- from slow-progressing individuals. This evidence concerns the gene NEFL and Alzheimer disease.